Shandong Sinobioway Biomedicine Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jialin Yue
Chief executive officer
CN¥1.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.5yrs |
| CEO ownership | n/a |
| Management average tenure | 2.5yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Jan 03
Shandong Sinobioway Biomedicine (SZSE:002581) Is In A Good Position To Deliver On Growth Plans
Dec 05There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump
Oct 08Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price
Aug 19Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues
Mar 06CEO
Jialin Yue (56 yo)
2.5yrs
Tenure
CN¥1,775,200
Compensation
Mr. Jialin Yue is GM & Director of Shandong Sinobioway Biomedicine Co., Ltd. since July 9, 2022 and August 5, 2022 respectively and was its Co-GM since April 10, 2022 until August 5, 2022. He serves as Cha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 2.5yrs | CN¥1.78m | no data | |
| Deputy GM & Non-Independent Director | 2.5yrs | CN¥1.02m | no data | |
| Board Secretary & Employee Director | 2.8yrs | CN¥1.16m | no data | |
| Deputy General Manager | 1.4yrs | CN¥625.40k | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data |
2.5yrs
Average Tenure
55.5yo
Average Age
Experienced Management: 002581's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 2.4yrs | CN¥1.78m | no data | |
| Deputy GM & Non-Independent Director | 2.4yrs | CN¥1.02m | no data | |
| Board Secretary & Employee Director | 2.4yrs | CN¥1.16m | no data | |
| Vice Chair | 9.1yrs | CN¥813.80k | no data | |
| Member of the Supervisory Board | 9.1yrs | no data | no data | |
| Director | 2.4yrs | CN¥649.90k | no data | |
| Non-Independent Director | 2.4yrs | CN¥531.00k | no data | |
| Independent Director | 2.4yrs | no data | no data | |
| Independent Director | 2.4yrs | CN¥100.00k | no data | |
| Independent Director | 2.4yrs | CN¥100.00k | no data |
2.4yrs
Average Tenure
52.5yo
Average Age
Experienced Board: 002581's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 10:54 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shandong Sinobioway Biomedicine Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|